Clinical Trials Browser

Has results × lorlatinib × Thoracic × Clear all

NCT03737994 2026-03-18

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Active not recruiting

10 enrolled 17 charts

Lung Neoplasms

NCT06282991 2026-03-10

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

73 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03052608 2025-11-25

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Phase 3 Active not recruiting

296 enrolled 28 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03909971 2025-11-05

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Phase 2 Completed

109 enrolled 33 charts

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04541706 2024-12-20

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Phase 4 Completed

100 enrolled 10 charts

Advanced Non-Small Cell Lung Cancer

NCT01970865 2024-08-12

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Completed

364 enrolled 89 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03726333 2024-06-21

Hepatic Impairment Study for Lorlatinib in Cancer Patients

Phase 1 Terminated

1 enrolled 3 charts

Lung Neoplasms, Neoplasms

NCT02584634 2023-07-07

Javelin Lung 101

Phase 1/2 Terminated

43 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

549 enrolled 28 charts

ALK-positive NSCLC